"A combination of concomitant boost thoracic radiation plus systemic chemotherapy appeared safe and effective among patients with locally advanced non–small cell lung cancer, according to phase 2 study results.
"Researchers evaluated accelerated hyperfractionation with concomitant boost thoracic radiation for 20 working days in doses of 64 Gy to the gross tumor volume, and 40 Gy to the elective clinical target volume. Patients also received cisplatin on day 1 and vinorelbine on days 1 and 8, with a 3-week interval."
Editor's Note: This story is about the results of a clinical trial. Clinical trials are research studies with volunteer patients. Many people who enroll in trials receive experimental treatments that they would not otherwise be able to have. Read more about how to see if a clinical trial is right for you: http://www.cancercommons.org/patients-caregivers/lung-cancer/the-basics-lung-cancer/#clinical